RWM
PCVX icon

Rialto Wealth Management’s Vaxcyte PCVX Stock Holding History

Rialto Wealth Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$640 Buy
+11
New +$597 ﹤0.01% 1553
2025
Q3 		– Sell
-15
Closed -$488 – 1768
2025
Q2 		$488 Buy
+15
New +$492 ﹤0.01% 1171

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Rialto Wealth Management's PCVX Position: Q2 2026 in Review

Rialto Wealth Management opened a new position in Vaxcyte (PCVX) in Q2 2026: 11 shares worth $640. The stake represents ﹤0.01% of the portfolio and ranks #1553 among its holdings. This is a return to the name: Rialto Wealth Management previously reported a position in PCVX as recently as Q2 2025.

Rialto Wealth Management first reported a position in PCVX in Q2 2025 and has held it in 2 quarters since. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Rialto Wealth Management held 11 shares of Vaxcyte worth $640 as of Q2 2026.
  • Vaxcyte was a new Rialto Wealth Management position in Q2 2026.
  • Vaxcyte made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #1553 holding.
  • Rialto Wealth Management first reported a position in Vaxcyte in Q2 2025 and has held it in 2 quarters since.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.